Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Harvard Business School
Medtronic
Moodys
McKesson

Last Updated: February 7, 2023

TRIFERIC AVNU Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


DrugPatentWatch® Generic Entry Outlook for Triferic Avnu

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 17, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for TRIFERIC AVNU
International Patents:12
US Patents:1
Applicants:1
NDAs:1
Clinical Trials: 11
Formulation / Manufacturing:see details
Drug Prices: Drug price information for TRIFERIC AVNU
What excipients (inactive ingredients) are in TRIFERIC AVNU?TRIFERIC AVNU excipients list
DailyMed Link:TRIFERIC AVNU at DailyMed
Drug patent expirations by year for TRIFERIC AVNU
Drug Prices for TRIFERIC AVNU

See drug prices for TRIFERIC AVNU

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TRIFERIC AVNU
Generic Entry Date for TRIFERIC AVNU*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIFERIC AVNU

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rockwell Medical Technologies, Inc.Phase 4
Rockwell Medical Technologies, Inc.Phase 3
Rockwell Medical Technologies, Inc.Phase 2

See all TRIFERIC AVNU clinical trials

US Patents and Regulatory Information for TRIFERIC AVNU

TRIFERIC AVNU is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TRIFERIC AVNU is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TRIFERIC AVNU

Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rockwell Medical Inc TRIFERIC AVNU ferric pyrophosphate citrate SOLUTION;INTRAVENOUS 212860-001 Mar 27, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRIFERIC AVNU

When does loss-of-exclusivity occur for TRIFERIC AVNU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 4754
Estimated Expiration: See Plans and Pricing

Canada

Patent: 38081
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0120416
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 13903
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 16940
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 16940
Estimated Expiration: See Plans and Pricing

Japan

Patent: 89196
Estimated Expiration: See Plans and Pricing

Patent: 09108027
Estimated Expiration: See Plans and Pricing

Poland

Patent: 16940
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 16940
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 16940
Estimated Expiration: See Plans and Pricing

Spain

Patent: 83713
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIFERIC AVNU around the world.

Country Patent Number Title Estimated Expiration
Spain 2383713 See Plans and Pricing
Denmark 2016940 See Plans and Pricing
Portugal 2016940 See Plans and Pricing
Poland 2016940 See Plans and Pricing
Japan 5489196 See Plans and Pricing
Austria 554754 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Boehringer Ingelheim
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.